亚虹医药(688176.SH)APL-1401Ⅰb期临床试验获积极初步结果

Core Viewpoint - The company, Yihong Pharmaceutical (688176.SH), announced positive preliminary results from its Phase Ib clinical trial of APL-1401 for the treatment of moderate to severe active ulcerative colitis [1] Group 1: Clinical Trial Details - The study is a randomized, double-blind Phase Ib trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patients with moderate to severe active ulcerative colitis [1] - The dose escalation of the study has been completed, demonstrating good safety [1] - Positive efficacy signals were observed within a treatment period of only 4 weeks [1]